Skip to main content
SpringerLink
Log in

Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington’s Disease

  • Protocol
Gene Therapy for Neurological Disorders

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1382))

Abstract

Huntington’s disease is a fatal neurodegenerative disease characterized by impairments in motor control, and cognitive and psychiatric disturbances. In this chapter, viral vector-mediated approaches used in modeling the key neuropathological features of the disease including the production of abnormal intracellular protein aggregates, neuronal dysfunction and degeneration and motor impairments in rodents are described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Martin JB, Gusella JF (1986) Huntington’s disease. Pathogenesis and management. N Engl J Med 315(20):1267–1276. doi:10.1056/NEJM198611133152006

    Article  CAS  PubMed  Google Scholar 

  2. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 72(6):971–983. doi:0092-8674(93)90585-E [pii]

    Google Scholar 

  3. Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85(15):5733–5737

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57(5):369–384

    Article  CAS  PubMed  Google Scholar 

  5. Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington’s disease. Nat Rev Neurosci 14(10):708–721. doi:10.1038/nrn3570

    Article  CAS  PubMed  Google Scholar 

  6. McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature 263(5577):517–519

    Article  CAS  PubMed  Google Scholar 

  7. Beal MF, Marshall PE, Burd GD, Landis DM, Martin JB (1985) Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington’s disease. Brain Res 361(1-2):135–145

    Article  CAS  PubMed  Google Scholar 

  8. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321(6066):168–171. doi:10.1038/321168a0

    Article  CAS  PubMed  Google Scholar 

  9. Roberts RC, Ahn A, Swartz KJ, Beal MF, DiFiglia M (1993) Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp Neurol 124(2):274–282. doi:10.1006/exnr.1993.1197, S0014-4886(83)71197-0 [pii]

    Article  CAS  PubMed  Google Scholar 

  10. Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 61(3):1147–1150

    Article  CAS  PubMed  Google Scholar 

  11. Borlongan CV, Koutouzis TK, Freeman TB, Cahill DW, Sanberg PR (1995) Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington’s disease. Brain Res 697(1-2):254–257, doi:0006-8993(95)00901-2 [pii]

    Article  CAS  PubMed  Google Scholar 

  12. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E (1997) Quantifiable bradykinesia, gait abnormalities and Huntington’s disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 79(1):45–56, doi:S0306452296006021 [pii]

    Article  CAS  PubMed  Google Scholar 

  13. Faber PW, Alter JR, MacDonald ME, Hart AC (1999) Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A 96(1):179–184

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C (2001) Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci U S A 98(23):13318–13323. doi:10.1073/pnas.231476398

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SL (1998) Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21(3):633–642

    Article  CAS  PubMed  Google Scholar 

  16. Lee WC, Yoshihara M, Littleton JT (2004) Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington’s disease. Proc Natl Acad Sci U S A 101(9):3224–3229. doi:10.1073/pnas.0400243101

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857):739–743. doi:10.1038/35099568

    Article  CAS  PubMed  Google Scholar 

  18. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23(1):181–192, doi:S0896-6273(00)80764-3 [pii]

    Article  CAS  PubMed  Google Scholar 

  19. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ (2001) Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 10(2):137–144

    Article  CAS  PubMed  Google Scholar 

  20. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493–506, doi:S0092-8674(00)81369-0 [pii]

    Article  CAS  PubMed  Google Scholar 

  21. Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF (2002) Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington’s disease knock-in mice. J Neurosci 22(18):8266–8276, 22/18/8266 [pii]

    CAS  PubMed  Google Scholar 

  22. Shelbourne PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandoski M, Ennis M, Ramirez L, Li Z, Iannicola C, Littman DR, Myers RM (1999) A Huntington’s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8(5):763–774, doi:ddc104 [pii]

    Article  CAS  PubMed  Google Scholar 

  23. Bayram-Weston Z, Jones L, Dunnett SB, Brooks SP (2012) Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington’s disease transgenic mice. Brain Res Bull 88(2-3):104–112. doi:10.1016/j.brainresbull.2011.07.009

    Article  CAS  PubMed  Google Scholar 

  24. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13):1555–1567

    Article  CAS  PubMed  Google Scholar 

  25. Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington’s disease transgenic mice. J Comp Neurol 490(4):354–370. doi:10.1002/cne.20680

    Article  PubMed  Google Scholar 

  26. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182–6195. doi:10.1523/JNEUROSCI.0857-08.2008

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, Nguyen HP (2012) A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J Neurosci 32(44):15426–15438. doi:10.1523/JNEUROSCI.1148-12.2012

    Article  CAS  PubMed  Google Scholar 

  28. Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD, Aebischer P, Deglon N (2005) Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis 20(3):785–798. doi:10.1016/j.nbd.2005.05.017

    Article  CAS  PubMed  Google Scholar 

  29. Huang B, Schiefer J, Sass C, Kosinski CM, Kochanek S (2008) Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion. J Gene Med 10(3):269–279. doi:10.1002/jgm.1150

    Article  CAS  PubMed  Google Scholar 

  30. Senut MC, Suhr ST, Kaspar B, Gage FH (2000) Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J Neurosci 20(1):219–229

    CAS  PubMed  Google Scholar 

  31. de Almeida LP, Ross CA, Zala D, Aebischer P, Deglon N (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 22(9):3473–3483, doi:20026337

    PubMed  Google Scholar 

  32. Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease. Mol Ther 16(5):947–956. doi:10.1038/mt.2008.50

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 104(43):17204–17209. doi:10.1073/pnas.0708285104

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, Deglon N (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65(3):276–285. doi:10.1002/ana.21569

    Article  CAS  PubMed  Google Scholar 

  35. Regulier E, Trottier Y, Perrin V, Aebischer P, Deglon N (2003) Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum Mol Genet 12(21):2827–2836. doi:10.1093/hmg/ddg305

    Article  CAS  PubMed  Google Scholar 

  36. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44(6):559–577

    Article  CAS  PubMed  Google Scholar 

  37. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Deglon N, Ferrante RJ, Bonvento G (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects. Hum Mol Genet 19(15):3053–3067. doi:10.1093/hmg/ddq212

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Palfi S, Brouillet E, Jarraya B, Bloch J, Jan C, Shin M, Conde F, Li XJ, Aebischer P, Hantraye P, Deglon N (2007) Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther 15(8):1444–1451. doi:10.1038/sj.mt.6300185

    Article  CAS  PubMed  Google Scholar 

  39. Burns LH, Pakzaban P, Deacon TW, Brownell AL, Tatter SB, Jenkins BG, Isacson O (1995) Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 64(4):1007–1017

    Article  CAS  PubMed  Google Scholar 

  40. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW (2008) Towards a transgenic model of Huntington’s disease in a non-human primate. Nature 453(7197):921–924. doi:10.1038/nature06975

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic, San Diego

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology & Clinical Pharmacology & Centre for Brain Research, School of Medical Sciences, University of Auckland, Auckland, New Zealand

    Deborah Young

Authors
  1. Deborah Young
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah Young .

Editor information

Editors and Affiliations

  1. Translational Science and Molecular Medicine, Michigan State University, College of Human Science, Grand Rapids, Michigan, USA

    Fredric P. Manfredsson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Young, D. (2016). Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington’s Disease. In: Manfredsson, F. (eds) Gene Therapy for Neurological Disorders. Methods in Molecular Biology, vol 1382. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3271-9_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3271-9_27

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3270-2

  • Online ISBN: 978-1-4939-3271-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation